Applying this HBB gene correction process to SCD patient-HSPCs results in over 50% expression of normal adult hemoglobin in mature red blood cells and in the correction of sickle phenotype, without inducing βthalassemic phenotype. Edited HSPCs engraft efficiently in an immunodeficient murine model and maintain clinically relevant levels of HBB gene correction events. This comprehensive preclinical data package sets the stage for the therapeutic application of autologous gene corrected HSPCs to address SCD. ...

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Cellectis leverages TALEN® technology and a non-viral gene repair template delivery to develop a clinically relevant gen ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and evaluated in ...

Cellectis S.A. (NASDAQ:CLLS) Q1 2024 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Arthur Stril - Interim-CFO André Choulika - CEO Mark Frattini - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dev Prasad - Jefferies Salveen Richter - Goldman Sachs Jack Allen - Baird Luisa Morgado - Van Lanschot Kempen Kuan-Hung Lin - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis First Quarter 2024 Earnings Call. [Operator Instructions] Please be a ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 28, 2024 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life- sav ...

Core Points - Cellectis, a clinical-stage biotechnology company, is set to hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET in Paris, France [1] - The company specializes in gene-editing technology to develop cell and gene therapies, particularly focusing on CAR-T immunotherapies for oncology [2] - Cellectis employs an allogeneic approach for CAR-T therapies, aiming to create off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has over 24 years of experience in gene editing and utilizes TALEN® technology and PulseAgile electroporation system [2] Company Overview - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, North Carolina [2] - The company is publicly traded on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [2] - Cellectis focuses on addressing unmet medical needs through innovative gene editing solutions [2]

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapie ...

as Exhibit 99.1 | --- | --- | --- | |--------------|---------------------------------------------------------------------------------------------------------|-------| | PART I – | FINANCIAL INFORMATION | 3 | | Item 1. | Interim Condensed Consolidated Financial Statements (Unaudited) | 3 | | Item 2. | Management's Discussion & Analysis of Financial Condition and Results of Operations | 42 | | Item 3. | Quantitative and Qualitative Disclosures About Market Risks | 52 | | Item 4. | Controls and Procedures | 52 ...

Core Viewpoint - Cellectis, a clinical-stage biotechnology company, is set to report its financial results for Q1 2024 on May 28, 2024, followed by an investor conference call on May 29, 2024, to discuss the results and business updates [1][2]. Company Overview - Cellectis specializes in developing life-saving cell and gene therapies using its gene-editing platform, focusing on CAR-T immunotherapies for oncology and therapeutic gene editing in hemopoietic stem cells [3]. - The company employs an allogeneic approach for CAR-T therapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [3]. - Cellectis has over 24 years of experience in gene editing and utilizes technologies such as TALEN® and PulseAgile to address unmet medical needs [3]. - The company is headquartered in Paris, France, with additional locations in New York and Raleigh, and is listed on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3].

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2024 ending March 31, 2024 on Tuesday, May 28, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024 at 8:00 ...